Skip to content

Umbrella review and meta‐analysis of antiplatelet therapy for peripheral artery disease

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)20-32
JournalBritish Journal of Surgery
Issue number1
Early online date6 Dec 2019
DateAccepted/In press - 5 Sep 2019
DateE-pub ahead of print - 6 Dec 2019
DatePublished (current) - 1 Jan 2020


Objective: The literature on antiplatelet therapy for peripheral arterial disease has historically been summarised inconsistently, leading to conflict between international guidleines. An umbrella review and meta-analysis was performed to clearly summarise the literature, allow assessment of competing safety risks and clinical benefits, and identify weak areas for future research.

Methods: MEDLINE, EMBASE, DARE, PROSPERO and Cochrane databases were searched from inception until January 2019. All meta-analyses of antiplatelet therapy in peripheral arterial disease were included. Quality was assessed using Amstar scores, with GRADE analysis quantifying strength of evidence. Data were pooled using random-effects models.

Results: Twenty-eight meta-analyses were included. Thirty-three clinical outcomes and 41 antiplatelet comparisons in 72,181 patients were analysed. High-quality evidence showed antiplatelet monotherapy reduced non-fatal strokes and cardiovascular death in symptomatic patients (3 and 8 fewer per 1000 patients respectively, 95% CI 0–6 and 0–16), but increased risk of major bleeding (7 more per 1000, 95% CI 3–14). In asymptomatic patients, monotherapy reduced non-fatal strokes (5 fewer per 1000, 95% CI 0–8) but had no other clinical benefit. Dual antiplatelet therapy caused more major bleeding after intervention than monotherapy (37 more per 1000, 95% CI 8–102), with very low-quality evidence of improved endovascular patency (Relative Risk 4.00, 95% CI 0.91–17.68).

Conclusions: Antiplatelet monotherapy has minimal clinical benefit for asymptomatic peripheral arterial disease, and limited benefit for symptomatic disease, with clear risk of major bleeding. There is a lack of evidence to guide antiplatelet prescribing after peripheral endovascular intervention which needs addressing by adequately powered randomised trials.

Study registration: PROSPERO 2017 CRD42017084223

    Research areas

  • antiplatelet therapy, peripheral arterial disease, systematic review, meta-analysis



  • Full-text PDF (author’s accepted manuscript)

    Rights statement: This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Wiley at . Please refer to any applicable terms of use of the publisher.

    Accepted author manuscript, 302 KB, PDF document

    Embargo ends: 6/12/20

    Request copy

    Licence: CC BY-NC


View research connections

Related faculties, schools or groups